Farmacogenómica de etanercept, infliximab, adalimumab y metotrexato en artritis reumatoide. Revisión estructurada

Caskey, 2010, Using genetic diagnosis to determine individual therapeutic utility, Annu Rev Med., 61, 1, 10.1146/annurev-med-011209-132719 Broder, 2000, Sequencing the entire genomes of free-living organisms: The foundation of pharmacology in the new millennium, Annu Rev Pharmacol Toxicol., 40, 97, 10.1146/annurev.pharmtox.40.1.97 Genetic Alliance; The New York-Mid-Atlantic Consortium for Genetic and Newborn Screening Services. Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals. Washington (DC): Genetic Alliance; 2009 Jul 8. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK115563/ Howard L McLeod, William E Evans. Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy. Department of Medicine, Division of Oncology, Washington University Medical School, St. Louis, Missouri. Annual Review of Pharmacology and Toxicology. Vol. 41: 101-121 (Volume publication date April 2001) DOI: 10.1146/annurev.pharmtox.41.1.101 Hertz, 2015, Pharmacogenetics of cancer drugs, Annu Rev Med., 66, 65, 10.1146/annurev-med-053013-053944 Andrade, Luis E.C. Future perspective for diagnosis in autoimmune diseases. Anais da Academia Brasileira de Ciências. vol.81 no.3 Rio de Janeiro Sept. 2009. On-line version. Divisão de Reumatologia, Universidade Federal de São Paulo, Escola de Medicina, Rua Botucatu, São Paulo, SP, Brasil. Disponible en: https://doi.org/10.1590/S0001-37652009000300004. Rielly, 2010, Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies, Pharmacogenomics Pers Med., 3, 15 Tougaard, 2016, Biologics beyond TNF-α inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders, Immunopharmacol Immunotoxicol., 38, 29, 10.3109/08923973.2015.1130721 Arora, 2013, Long-term drug survival of TNF inhibitor therapy in RA patients: A systematic review of european national drug registers, Int J Rheumatol., 2013, 764518, 10.1155/2013/764518 Agarwal, 2008, Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis, J Rheumatol., 35, 1737 Arribas, Ignacio Andrés. Farmacogenética y Variabilidad Interindividual. En: La Respuesta a los Medicamentos, 23 de Marzo de 2010. Academia de farmacia «Reino de Aragón» Zaragoza, [consultado 5 Abr 2016]. Disponible en: http://www.academiadefarmaciadearagon.es/docs/documentos/documento21.pdf Instituto Canario de Investigación del Cáncer. Research Journal ISS 1697-6452 [consultado 25 Abr 2016]. Disponible en: http://www.biocancer.com/journal/272/3-la-variacion-genica Tanaka, 2004, Pharmacogenetics of disease-modifying anti-rheumatic drugs, Best Pract Res Clin Rheumatol., 18, 33, 10.1016/j.berh.2004.02.006 Prajapati, 2011, Genetic and genomic predictors of anti-TNF response, Pharmacogenomics., 12, 1571, 10.2217/pgs.11.114 Benito Ruiz, 2001, ¿Por qué un tratamiento precoz en la artritis reumatoide?, Medifam., 11, 10.4321/S1131-57682001000600005 Muñetón Gerardo, 2015, La epidemiología de la artritis reumatoide, Rev Colomb Reumatol., 22, 145 Prajapati, 2011, Genetic and genomic predictors of anti-TNF response, Pharmacogenomics., 12, 1571, 10.2217/pgs.11.114 Zhou, 2008, Clinical pharmacogenetics and potential application in personalized medicine, Curr Drug Metab, 9, 738, 10.2174/138920008786049302 Widdifield, 2014, The epidemiology of rheumatoid arthritis in Ontario, Canada, Arthritis Rheumatol., 66, 786, 10.1002/art.38306 Malemba, 2012, The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo—A population-based study, Rheumatology., 51, 1644, 10.1093/rheumatology/kes092 Neovius, 2011, Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden, Ann Rheum Dis., 70, 624, 10.1136/ard.2010.133371 Scublinsky, 2010, The prevalence of rheumatoid arthritis in Argentina: A capture-recapture study in a city of Buenos Aires province, J Clin Rheumatol., 16, 317, 10.1097/RHU.0b013e3181f3bfdd Senna, 2004, Prevalence of rheumatic diseases in Brazil: A study using the COPCORD approach, J Rheumatol., 31, 594 Silman, 2002, The changing face of rheumatoid arthritis: Why the decline in incidence?, Arthritis Rheum., 46, 579, 10.1002/art.508 Gorman, 2004, Impact of shared epitope genotype and ethnicity on erosive disease: A meta-analysis of 3240 rheumatoid arthritis patients, Arthritis Rheum., 50, 400, 10.1002/art.20006 Mateen, 2016, Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis, Clinica Chimica Acta., 455, 161, 10.1016/j.cca.2016.02.010 Uribe, 2010 Wilkinson, 2005, Drug metabolism and variability among patients in drug response, N Engl J Med., 352, 2211, 10.1056/NEJMra032424 Wijnen, 2007, The prevalence and clinical relevance of cytochrome P450 polymorphisms, Aliment Pharmacol Ther., 26, 211, 10.1111/j.1365-2036.2007.03490.x Johnson, 2013, Pharmacogenetics and cardiovascular disease-implications for personalized medicine, Pharmacol Rev., 65, 987, 10.1124/pr.112.007252 Duke Medicine. 2011. Personalized medicine. En: USA News, publicado el 20 de enero de 2011. Disponible en: http://health.usnews.com/health-conditions/cancer/personalized-medicine Lee, 2016, Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: A meta-analysis, Rheumatol Int., 36, 837, 10.1007/s00296-016-3476-5 Sode, 2015, Genetic variations in pattern recognition receptor loci are associated with anti-TNF response in patients with rheumatoid arthritis, PLoS One., 10, e0139781, 10.1371/journal.pone.0139781 Montes, 2014, Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis, Pharmacogenet Genomics., 24, 238, 10.1097/FPC.0000000000000042 Dávila-Fajardo, 2014, Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome, Pharmacogenet Genomics., 24, 1, 10.1097/FPC.0000000000000013 Morales-Lara, 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis, Joint Bone Spine., 79, 591, 10.1016/j.jbspin.2012.02.003 Honne, 2016, A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis, Arthritis Res Ther., 18, 12, 10.1186/s13075-016-0920-6 Canhão, 2015, TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy, Biomed Res Int., 2015, 490295, 10.1155/2015/490295 Montes, 2015, FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors, Pharmacogenomics., 16, 333, 10.2217/pgs.14.175 Morales-Lara, 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis, Joint Bone Spine., 79, 591, 10.1016/j.jbspin.2012.02.003 Muralidharan, 2016, ATIC 347C>G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis, Pharmacogenomics., 17, 241, 10.2217/pgs.15.170 Salazar, 2014, Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?, Pharmacogenomics., 15, 1079, 10.2217/pgs.14.67 Moya, 2016, Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients, Pharmacogenomics., 17, 25, 10.2217/pgs.15.150 Lee, 2016, Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis: A meta-analysis, Z Rheumatol., 75, 707, 10.1007/s00393-015-1618-x Ghodke-Puranik, 2015, Folate metabolic pathway single nucleotide polymorphisms: A predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis, Pharmacogenomics., 16, 2019, 10.2217/pgs.15.145 Uribarri, 2015, Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: Results from the GAPAID European project, Clin Exp Rheumatol., 33, 699 Chaabane, 2016, Genetic determinants of methotrexate toxicity in Tunisian patients with rheumatoid arthritis: A study of polymorphisms involved in the MTX metabolic pathway, Eur J Drug Metab Pharmacokinet., 41, 385, 10.1007/s13318-015-0288-z Lima, 2015, Pharmacogenomics of methotrexate membrane transport pathway: Can clinical response to methotrexate in rheumatoid arthritis be predicted?, Int J Mol Sci., 16, 13760, 10.3390/ijms160613760 Muralidharan, 2015, Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis, Eur J Clin Pharmacol., 71, 959, 10.1007/s00228-015-1885-0 Lima, 2014, SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients, Toxicol Sci., 142, 196, 10.1093/toxsci/kfu162 Samara, 2014, Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients, Int J Clin Pharmacol Ther., 52, 746, 10.5414/CP202098